Regenerative Medicine and Stem Cells Technologies

According to the report of Public Relations and International Affairs of Council for Development of Stem Cell Sciences and Technologies,citing the Research Institute of Oncology, Hematology and Tuberculosis Therapy, in this meeting that was held on Monday, November 30, Dr. Vaezi, the head of the research institute, presented a brief report on the activities of the oncology, hematology, and tuberculosis research centers and continued: "The activities of the tuberculosis therapy center were neglected in the past and practically no articles from this center had been published, which fortunately The continuous efforts of this center's activities have also been resumed in the form of eight joint research projects with other research centers.

He also considered the use of the available capacity in the field of tuberculosis therapy as a suitable opportunity to carry out research work based on the needs of patients, which will be possible in the shadow of constructive interaction with other centers. Then, Dr. Hamidieh, the secretary of the stem cell science and technology development staff of the vice president's science and technology office, announced the readiness of the staff to provide all kinds of services, including the establishment of accelerators and mentoring of technological cores to transform research institutes into knowledge-based companies. And he stated that there is a common synergy between the Vice-Chancellor of Science and Technology and Tehran University of Medical Sciences in this field. He also considered Shariati Hospital's general status as a good opportunity to establish numerous technology centers. Referring to the issue of transplantation in non-hematological malignancies, he said: "Since last year, England has removed drug insurance for MS and uses hematopoietic cell transplantation to treat it. Due to the high cost of drug treatment this disease is affecting the country, the capacity available in this research institute can be used to transplant patients with MS, and since this research institute consists of three research centers, there is no limit in terms of the establishment of technology cores.

In the following, Dr. Vaezi pointed out the use of available capacities in tuberculosis therapy in the treatment of MS disease with the help of autologous transplantation in the form of a joint project with Sinai Hospital and introduced the use of NK cells in solid tumors in the form of joint proposals as another step to enter this field. . He also considered the use of T cells in the treatment of BK and CMV in the form of two approved research projects as another effective step in using the existing potentials. He further mentioned the initial negotiations with the Barkat Foundation in order to use mRNA technology in tumor vaccines and also the preparation of a joint clinical proposal with Royan in the field of CAR T Cell. He also announced the possibility of entering the field of CAR-NK Cells due to its safety in the near future.

 Dr. Vaezi Hamjanin pointed to the diligent efforts of the research institute to resume international interactions for the purpose of exchanging information and requested the university's support to realize this. In another part of his speech, he mentioned about performing clinical activities in a clean room and considered the need for a standard tuberculosis therapy department to provide the best possible services and use the potential, and requested the assistance of the hospital and university to achieve the goals. Commenting and presenting new ideas. He also added that the establishment of a therapeutic biobank and a research biobank is one of the research institute's priorities, which must be realized in the near future. At the same time, considering the type of clinical work and the type of studies that are mainly clinical, efforts to create a clinical trial unit and standardize it are other priorities of the research institute. In addition, Dr. Jamshidi, the head of Shariati Hospital, stated that we are witnessing a new development and dynamism during the presidency of Dr. Vaezi, he emphasized on all-round support for the programs of the research institute, but at the same time, in order to preserve the existing facilities and potentials, he wants to stop parallel work. It was implemented in carrying out projects. Then Dr. Fatuhi, vice president of research and technology of the university, said: "There are significant and diverse capacities and potentials in the university, on the basis of which we defined the areas of the edge of knowledge, the first area of which is the discussion of stem cells, which was given during the call We have received 27 projects so far, and we are trying to ensure that only product-oriented projects are included in the agenda of the university, and for this, significant credit has been considered. He further said about the limitations of research projects: "There is no ceiling or floor for presenting a research project, but it requires the logical management of previous projects and observance of moderation." In the case of mRNA, he pointed to the potential capacities and potentials available in the university and clarified that currently, Renap mRNA is in the clinical phase and it is the only Renap mRNA that has obtained permission for human injection from the Food and Drug Organization. He also added that Dr. Hamidiyeh has been tasked to divide the duties in different parts of the field of tuberculosis therapy in order to prevent parallel work. In the end, Dr. Hamidieh explained some of the activities of the headquarters to achieve the set goals and pointed out that the budget allocated to the law on the youth of the population and family support, which includes three areas of childbearing, infertility, and mother and child health, in The headquarters of stem cell science and technology development is under the authority of the Presidential Vice President for Science and Technology, so oncology research can be carried out in the field of breast, ovarian and uterine cancer and everything related to women's cancer. He also considered the umbilical cord bank as well as the gynecology and obstetrics department of Shariati Hospital as a suitable opportunity that can be made possible by upgrading it to a refinery of maternity products. He also emphasized on the assistance of the stem cell science and technology development headquarters of the Presidential Vice President for Science and Technology in the matter of technological research in Shariati Hospital.